Home
About
Disclaimer
Privacy

JCS/T2D - We are advocates. We learn. We share. We inform.

Enter Part of Title

Display #

Disclaimer

Articles

The Dual Roles of GLP-1 and GLP-2 in Metabolic Health
The Economic Impact of Ozempic on Denmark
New York Takes a Bold Step to Tackle Insulin Affordability
GLP-1 Drugs and Suicidal Thoughts: A Comprehensive Review by Regulators
Regulatory Hurdles for Awiqli: Approval in Canada and EU, Concerns in the US
Understanding the Link Between Type 2 Diabetes and Chronic Kidney Disease
Cigna's Bold Step Forward: Making Weight-Loss Medications More Accessible
The Manufacturing Costs and Supply Chain Dynamics of Diabetes Drugs
Tirzepatide’s Efficacy in Treating Obstructive Sleep Apnea
The Mounjaro Supply Challenges: Looking Back and Looking Forward
Summary of the Study on Body Size Change and Risk of Type 2 Diabetes and Cardiovascular Disease
Novo Nordisk Announces Positive Results in Phase 3a Trial of IcoSema, a Combination of Semaglutide and Insulin Icodec for Type 2 Diabetes
Tirzepatide and the Future of Incretin Therapies: A New Horizon in Obesity Treatment
A New Era in Diabetes Management: Once-Weekly Insulin Icodec
GLP-1 RAs and Gastroparesis (Stomach Paralysis)
Eli Lilly's Stance on Tirzepatide for Cosmetic Use
Navigating Prior Authorization for Type 2 Diabetes Treatments
Revolutionizing Diabetes and Obesity Care with AI at Novo Nordisk
The Potential of GLP-1 Medications for Type 1 Diabetes
The Power of Exercise and Music in Managing Type 2 Diabetes

News

October 2025

FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
Innovent’s Mazdutide Outperforms Semaglutide in Head-to-Head Trial
Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
Semaglutide’s Heart Benefits Extend Beyond Weight Loss
Terns Ends Development of Oral Obesity Drug After Phase 2 Results

September 2025

CVS Caremark Faces Lawsuit Over Dropping Zepbound
Dexcom Introduces Smart Basal at EASD 2025
Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
Novo Nordisk Resubmits Once-Weekly Basal Insulin Awiqli® for FDA Review
Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration

August 2025

FDA Approves Wegovy for MASH Treatment
FDA Expands Repatha Access to More High-Risk Adults
Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
Signos Press Release Raises Questions About FDA Clearance Claims
Teva Launches First Generic GLP-1 for Obesity
Wegovy Outperforms Mounjaro in Cardiovascular Outcomes

Top Subjects

Type 2 Diabetes
Novo Nordisk
Semaglutide
Obesity Treatment
GLP-1
Wegovy
Eli Lilly
Tirzepatide
Ozempic
Zepbound
Diabetes
Obesity
FDA Approval
Diabetes Management
Cardiovascular Health
Mounjaro
SELECT Trial
Continuous Glucose Monitoring
GLP-1 Therapy
Obesity Management
Metabolic Health
Orforglipron
Disease Modification
Dexcom
CGM
Rybelsus
Clinical Trials
Oral Semaglutide
FDA
Diabetes Treatment

Contact Us

How many eyes does a typical person have?

Search

Search

You are here:
Home
JCS/T2D - A Diabetes Journey

Copyright © 2025 JCS/T2D - A Diabetes Journey. All Rights Reserved.

Joomla! is Free Software released under the GNU General Public License.